Intelligent Bio SolutionsINBS
INBS
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 8 [Q3] → 8 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4.19% less ownership
Funds ownership: 5.94% [Q3] → 1.75% (-4.19%) [Q4]
75% less capital invested
Capital invested by funds: $437K [Q3] → $108K (-$329K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for INBS.
Financial journalist opinion
Based on 6 articles about INBS published over the past 30 days
Positive
Zacks Investment Research
13 hours ago
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.
Neutral
GlobeNewsWire
16 hours ago
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in Spain and Andorra through a strategic collaboration with Detecto, a division of Spanish distributor MTB Distribuciones Tecnologicas SL ("MTB"). MTB established Detecto following decades of experience in clinical distribution, recognizing the market's evolving needs and increasing demand for drug testing across various sectors.
Neutral
GlobeNewsWire
1 day ago
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
Company's 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
Neutral
GlobeNewsWire
2 days ago
Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a status update on the FDA clearance process for its Intelligent Fingerprint Drug Screening System, which remains on track for launch in the U.S. in 2025 targeting its opiate test system for codeine, as validated in the Company's Pharmacokinetic (PK) study. On December 18, 2024, the Company announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and clearance of its Intelligent Fingerprinting Drug Screening System, which the FDA classified as a 21 CFR 862.3650, Opiate Test System, a Class II device requiring submission of a 510(k) premarket notification.
Neutral
GlobeNewsWire
1 week ago
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its sixth patent in the United States, which will strengthen the protection of the lateral flow technology core to its Intelligent Fingerprinting Drug Testing Solution.
Neutral
GlobeNewsWire
2 weeks ago
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025.
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter's Option to Purchase Additional Shares of Common Stock
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock at a public offering price of $2.00 per share of common stock, which included the full exercise of the underwriter's option to purchase up to 195,652 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from the offering were approximately $3.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6 million, before deducting underwriting discounts and commissions and offering expenses.
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six months ended December 31, 2024, and provided a business update. "Fiscal Q2 was a successful quarter for the business in a number of areas.
Charts implemented using Lightweight Charts™